GC Pharma (Formerly known as Green Cross)

40 articles with GC Pharma (Formerly known as Green Cross)

• US FDA Accepts GC Pharma’s Biologics License Application for Immune Globulin 'GC5107'

  5/5/2021

  GC Pharma announced that the United States Food and Drug Administration accepted the company’s Biologics License Application for 'GC5107,10% Liquid)’ intended for the treatment of Primary Humoral Immunodeficiency, a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system.

• GC Pharma Reports Q1 2021 Results

  4/29/2021

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for the three months ended 31 March 2021.

• GC Pharma Finalises Agreement With Moderna and the Government of the Republic of Korea for COVID-19 Vaccines Distribution

  3/4/2021

  GC Pharma announced that it will support Moderna and the government of the Republic of Korea in the distribution of 40 million doses of COVID-19 Vaccine Moderna, Moderna’s vaccine candidate against COVID-19, to support South Korea’s aim of providing vaccines to the public in a timely manner, subject to necessary local regulatory approvals.

• GC Pharma Submits Biologics License Application to US FDA for Immune Globulin 'GC5107'

  2/26/2021

  GC Pharma announced that it had submitted its Biologics License Application for 'GC5107',10% Liquid) to the United States Food and Drug Administration.

• GC Pharma Reports Full Year 2020 Results

  2/9/2021

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited financial results for the year ended 31 December 2019.

• GC Pharma Reports Q3 2020 Results

  11/2/2020

  GC Pharma, a South Korean biopharmaceutical company, announced unaudited consolidated financial results for third quarter of 2020.

• GC Pharma Reports Q2 2020 Results

  7/30/2020

  GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for second quarter of 2020. Second-Quarter Reported Results (1) Key Figures (1) Q2 2020 Growth (2) Total revenues

• Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million

  7/20/2020

  Grifols makes a significant investment to become the only large-scale commercial manufacturer of plasma products in Canada, with a fractionation capacity of 1.5 million liters/year

• 

  Biopharma Update on the Novel Coronavirus: May 8

  5/8/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 8, 2020.

• GC Pharma Reports Q1 2020 Results

  4/29/2020

   GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited consolidated financial results for the three months ended 31 March 2020 . First-Quarter Reported Results (1)

• GC Pharma lights up to celebrate 'World Hemophilia Day'

  4/17/2020

  GC Pharma, a South Korean biopharmaceutical company, participate in campaign to celebrate World Hemophilia Day.

• GC Pharma Reports Full Year 2019 Results

  2/12/2020

  All consolidated entities revenues grew plus compared to prior year YONGIN, South Korea , Feb. 12, 2020 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2019 . Key Figures (1 ) Full Year 2019 (2 )

• GC Pharma Reports Q3 2019 Results

  10/30/2019

  Double-digit profit growth through strong profitable business sales

• Vaxess and GC Pharma to Collaborate on Development of Highly Effective Influenza Vaccine Smart Release Patch

  10/16/2019

  Vaxess will have exclusive rights to commercialize the MIMIX Flu Smart Release Patch in the US and Europe, while GC Pharma obtains rights for the South Korean market

• GC Pharma Reports Q2 2019 Results

  7/30/2019

  Profitability has improved Through International expansion

• GC Pharma Reports Q1 2019 Results

  4/30/2019

  Profitability is expected to improve from Q2 and on

• GC Pharma Marks 'World Hemophilia Day'

  4/16/2019

  The Company Joins the Bleeding Disorder's Community to Celebrate

• Clinigen K.K. and GC Pharma Announce Exclusive Licensing Agreement in Japan for Hunterase (Idursulfase-beta) ICV, Hunter Syndrome Drug

  4/4/2019

  Clinigen K.K. and GC Pharma announced an exclusive licensing agreement in Japan to commercialize Hunterase ICV, a human recombinant iduronate-2-sulfatase used in enzyme replacement therapy for the treatment of Hunter syndrome.

• GC Pharma Reports Full Year 2018 Results

  2/12/2019

  GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended 31 December 2018.

• CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome

  1/7/2019

  CANbridge Pharmaceuticals Inc. announced an exclusive licensing agreement in the greater China area to commercialize Hunterase™, a human recombinant iduronate-2-sulfatase (IDS) enzyme replacement therapy for the treatment of Hunter syndrome.